The LanthaScreen®ATF2 (19-106) A549 cell line contains a fusion protein consisting of GFP and a fragment encoding for aa 19-106 of ATF2 under the control of a CMV promotor. A549 is a lung carcinoma cell line which shows inducible activation of JNK by number of different ligands, such as TNF and EGF, which leads to the transient phosphorylation of GFP-ATF2 (19-106). This LanthaScreen®cell line therefore allows the analysis of JNK activity using GFP-ATF2 phosphorylation as readout. The GFP-ATF2 (19-106) construct was transfected into A549 cells using Lipofectamine™2000, followed by selection with Blasticidin. This cell line is a clonal population isolated by flow cytometry using GFP fluorescence as sorting marker. This cell line is validated for EC50 and Z' under optimized conditions using TNF as ligand for JNK mediated GFP-ATF2 (19-106) phosphorylation. This cell line has been tested for assay performance under variable experimental conditions, including cell plating density, stimulation time, DMSO tolerance and assay development time. Additional information using alternate stimuli is also available. Academic and non-profit customers, please inquire for special pricing.